Among its currently approved cancer drugs, Kyprolis is Onyx's most important growth driver with 2018 consensus sales of $1.9 billion.
Kyprolis is currently approved in the U.S. as a treatment for multiple myeloma patients who no longer respond to other therapies, but Onyx is conducting clinical trials to demonstrate the drug's efficacy in patients with newly diagnosed cancer. The company also intends to get Kyprolis approved in Europe.
Importantly but perhaps overlooked by many investors, Onyx also gets an 8 percent royalty on future sales of an experimental and very exciting Pfizer (PFE - Get Report) breast cancer drug known as palbociclib.
"The market opportunity for
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts